Growth factor modified extracellular matrix material preparation and methods for preparation and use thereof
View Patent ↗Described are tissue graft constructs that include submucosa and other extracellular matrix materials that incorporate a number of exogenous proteins. Further described are methods for making tissue graft constructs that include stripping endogenous heparin binding proteins from a porcine graft material and thereafter binding one or more human growth factors to the native heparin molecules that are retained within the graft material. Such graft materials may be used in methods for the treatment of wounds in patients.
1. A medical graft product, comprising:
an extracellular matrix material retaining native heparin molecules, wherein the extracellular matrix material is substantially depleted of native heparin binding proteins and contains non-native heparin binding proteins bound to the native heparin molecules.
2. The medical graft product of claim 1 , wherein the extracellular matrix material comprises submucosa, dermal collagen, dura mater, pericardium, or basement membrane.
3. The medical graft product of claim 2 , wherein the submucosa comprises mammalian submucosa.
4. The medical graft product of claim 3 , wherein the mammalian submucosa comprises porcine submucosa.
5. The medical graft product of claim 4 , wherein the porcine submucosa comprises small intestine submucosa.
6. The medical graft product of claim 1 , wherein the non-native heparin binding proteins include exogenous growth factors.
7. A medical graft product for healing a wound in a patient, comprising:
an extracellular matrix material; and
one or more exogenous growth factors, wherein the exogenous growth factors are bound to native heparin binding sites retained within the extracellular matrix material.
8. The medical graft product of claim 7 , wherein the one or more exogenous growth factors comprise fibroblast growth factor, heparin binding epidermal growth factor (HBEGF), vascular endothelial growth factor (VEGF), placental growth factor (PIGF), heparin-binding EGF-like growth factor, transforming growth factor-beta (TGF-beta), interferon-gamma (IFN-gamma), platelet-derived growth factor (PDGF), pleiotrophin, interleukin-8 (IL-8), or any suitable combination thereof.
9. The medical graft product of claim 8 , wherein fibroblast growth factor includes FGF-1 (aFGF), FGF-2 (bFGF), FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, or any suitable combination thereof.
10. The medical graft product of claim 7 , wherein the one or more exogenous growth factors facilitate a specific response in patient tissue.
11. The medical graft product of claim 7 , wherein the extracellular matrix material comprises porcine extracellular matrix material and the one or more exogenous growth factors comprise human growth factors.
12. A medical graft product for facilitating the repair of patient tissue, comprising:
a collagenous material, wherein the collagenous material includes endogenous heparin molecules to which exogenous heparin binding proteins are bound, wherein the exogenous heparin binding proteins are effective to facilitate tissue repair.
13. The medical graft product of claim 12 , wherein the collagenous material comprises an extracellular matrix material.
14. The medical graft product of claim 13 , wherein the extracellular matrix material comprises a multilaminate extracellular matrix material.
15. The medical graft product of claim 13 , wherein the extracellular matrix material comprises a sheet material.
16. The medical graft product of claim 12 , wherein the exogenous heparin binding proteins comprise one or more human growth factors.
17. A medical graft product for tissue repair in a patient, comprising:
a sterile, remodelable, and collagenous extracellular matrix material retaining native heparin molecules and substantially depleted of native heparin binding proteins.
18. The medical graft product of claim 17 , wherein the collagenous extracellular matrix material comprises small intestine submucosa.
19. A medical graft product for repairing patient tissue, comprising:
a collagenous remodelable material having native heparin molecules bound to non-native growth factors, wherein the collagenous remodelable material is porcine and the non-native growth factors are human.